- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Low Tumor Metabolic Activity Could Predict Survival in Stage I NSCLC
Low pre-surgery uptake of a labeled glucose analogue, a marker of metabolic activity, in the primary tumor of patients with stage I non-small cell lung cancer is associated with increased overall survival and a longer time before tumor recurrence, a study shows. Patients with high labeled glucose uptake may benefit from additional therapy following surgery.
Surgery is the standard of care for patients with stage I non-small cell lung cancer (NSCLC) but not all patients are cured, as demonstrated by a 5-year survival rate of less than 60% in these patients. There is a clear need for a diagnostic test to identify which patients should receive post-surgical therapy, such as chemotherapy, and which patients don't need further treatment, thus avoiding unnecessary treatment related toxicity and complications. Fluorodeoxyglucose (FDG) is radiolabeled analogue of glucose whose concentration within a tumor can be measured with a positron emission tomography (PET) imaging scanner.
Researchers from Duke University Medical Center reviewed 336 patients diagnosed between 2005 and 2010 with stage I NSCLC who underwent FDG/PET within 90 days of surgery to determine if FDG uptake, as measured by maximum standard uptake value (SUVmax) with PET, was associated with overall survival or time to recurrence. The median follow-up was 5.1 years.
Link to the complete article on ScienceDaily:
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
NCCN Data Find Racial, Socioeconomic Disparities in Quality of Care for Metastatic Pancreatic Cancer
April 9th 2025New data from the National Comprehensive Cancer Network (NCCN) reveal that socially vulnerable and minority patients with metastatic pancreatic cancer are less likely to receive recommended treatments and achieve longer survival.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
